SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

LifeSci Capital initiates BlossomHill Therapeutics at Outperform

LifeSci Capital initiated BlossomHill Therapeutics with an Outperform rating and set a $32.00 price target per share, per Benzinga via TradingView News.

BLSM

BlossomHill Therapeutics was initiated at Outperform by LifeSci Capital, according to a Benzinga ratings action.

Related stories